Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
were adopted early on during the epidemic peak. Since March 13th, segregated inpatient and outpatient facilities of the Oncology section and organizational changes trajectories were observed when comparing pts grouped by discharge/O2/death. Higher CRP and LDH at diagnosis were associated with admission (p<0.0001). Platelets were significantly reduced during VERSUS PRE COVID-19 (p=0.0028). 17/52 pts developed transient (median 2 days) neutropenia (≤2x10^9/L) during infection (6 pts <1x10^9/L, 2 pts <0.5x10^9/L). 17/41 pts received growth factor support. Reduced lymphocytes/neutrophils/platelets at diagnosis were not associated with oxygen requirement (O2) or death. Different CRP trajectories were observed when comparing pts grouped by discharge/O2/death. Higher CRP and LDH at diagnosis were associated with admission (p=0.02 CRP/0.2 LDH). O2 (p=0.0002 CRP/p=0.01 LDH) and death (p=0.069 CRP/p=0.04 LDH). Updated analysis will be presented.

Conclusions: Infection with SARS-CoV-2 commonly affects haematological parameters in cancer pts. High CRP and LDH are associated with poor outcomes.

Legal entity responsible for the study: The Christie NHS Foundation Trust.

Funding: Has not received any funding.

Disclosure: R. Lee: Speaker Bureau/Expert testimony, Research grant (Funding) (Self), Bristol Myers Squibb; Speaker Bureau/Expert testimony: Astra Zeneca. A. Armstrong: Shareholder/Stockholder/Stock options, Husband had declared: Astra Zeneca. T. Cooksey: Solicitor Bureau/Expert testimony. Bristol Myers Squibb. All other authors have declared no conflicts of interest.

https://doi.org/10.1016/j.annonc.2020.08.1786

Organizational challenges and oncological activity volumes during the SARS-CoV-2 epidemic peak in Verona, Italy

S. Meleì1, S. Zuliani1, J. Zampiva1, D. Tregnago1, M. Casali1, A. Cavalliere1, A. Fumagalli1, S.T. Riva1, A. Rossi1, F. Zacchi1, E. Zaninotto1, A. Auriemma3, M. Pavarana2, C. Soldà3, L. Benini1, M. Borghesani1, G. Lo Cascio2, E. Tacconelli4, F.M. Uckun3, Z. Arik1

1Medical Oncology, University of Verona - Faculty of Medicine, Verona, Italy; 2Medical Oncology, University of Verona Hospital Trust, Verona, Italy; 3Medical Oncology Department, University of Verona Hospital Trust, Verona, Italy; 4Infectious Diseases, University of Verona - Faculty of Medicine, Verona, Italy

Background: On February 23rd the first case of SARS-CoV-2 infection was diagnosed at the University Hospital Trust of Verona, Italy. On March 13th, the Oncology Section was converted into a 22 inpatient beds COVID unit and we had to reshape our organization and personnel to face the SARS-CoV-2 epidemic, while maintaining our oncological activity.

Methods: We tracked down oncological activity from January 1st to March 31st, 2020, in relationship to the organizational changes implemented and in comparison to the same period of 2019. We also recorded cases of SARS-CoV-2 infection observed in oncology health professionals and hospital admissions of active oncology patients for SARS-CoV-2 infection.

Results: Progressive restrictions in patients’, visitors’, and caregivers’ access to the inpatient and outpatient facilities of the Oncology section and organizational changes were observed during the epidemic peak. Since March 13th, segregated personnel teams were created, one dedicated to the COVID unit and a “clean” one dedicated to oncological patients, resulting in an overall 40% and 43% reduction in oncology/dedicated medical and nursing/auxiliary staff, respectively. As compared with the same intervals in 2019, the overall reduction in total numbers of inpatient admissions, chemotherapy administrations, and specialty visits in the period January-March 2020 was 8%, 6%, and 3%, respectively; based on the weekly average of daily admissions, reduction in some of the oncological activities became statistically significant from week 11. Patient’s acceptance of adopted measures was very high (see abstract by Tregnago D). Overall, 8/85 (9%) health professionals tested positive for SARS-CoV-2 (no hospital admissions and no treatment required) and 7/525 (1.3%) active oncology patients were admitted for SARS-CoV-2 infection (of whom, 2 died of infection-related complications).

Conclusions: A minimal (<1%) reduction in Oncology activity was registered during the peak of SARS-CoV-2 epidemic in Verona, Italy. Organizational and protective measures adopted appear to have contributed to keep infections in both health professionals and oncological patients to a minimum.

Legal entity responsible for the study: University of Verona.

Funding: Has not received any funding.

Disclosure: All authors have declared no conflicts of interest.

https://doi.org/10.1016/j.annonc.2020.08.1787

Changes in the outpatient and inpatient admissions during COVID-19 pandemic: Anticipating and mitigating risks for cancer patients

D.C. Guven1, B.Y. Aktaş1, M.S. Aksoy1, E. Uğurlu1, T.K. Sahin1, H.C. Yıldırım1, G. Gündüz1, N. Kertmen1, O. Dişdar1, S. Kiliçkap1, S. Aksoy1, Ş. Yalçın1, A. Turker1, F.M. Uckun1, Z. Arik1

1Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey; 2Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey; 3COVID-19 Task Force, Worldwide Clinical Trials, Wayne, PA, USA

Background: Prioritizing the continuum of care for cancer patients while maximizing patient safety is of paramount importance. However, COVID-19 pandemic could result in collateral damage in all domains of cancer care. Here, we evaluated the early changes in the inpatient and outpatient oncology clinics and discuss how we currently anticipate and mitigate risks for cancer patients at the Hacettepe University Cancer Institute by employing adaptive algorithms.

Methods: Patients applying the outpatient clinic and outpatient palliative care (OPC) clinic for the first time and patients admitted to wards in the first 30 days after the first case of COVID-19 in Turkey were evaluated. This data was compared to data from the same time frame in the previous three years.

Results: A total of 888 inpatient and 809 outpatient admissions were evaluated in the study with a 114 OPC clinic admissions. The mean number of daily new patient applications to the outpatient clinic (9.87±3.87 vs. 6.43±1.43, p<0.001) and OPC clinic (3.87±1.49 vs. 1.13±1.46, p<0.001) was significantly reduced compared to the previous years. The reduction in new patient numbers was observed for all tumor types with the exception of lung and head and neck cancers. While the number of inpatient admissions was similar for a month frame (228 vs. 213), the median duration of hospitalization was significantly reduced (2 vs. 3 days). The frequency of hospitalizations for chemotherapy was higher than in previous years (p<0.001). By comparison, the rate of hospitalizations for palliative care (P=0.028) or elective interventional procedures (P<0.001) was significantly reduced.

Conclusions: In our experience, continuing the patients’ treatment with simple pre-conditions was possible with simple measures. There were significant drops in the numbers of newly diagnosed patients and patients having palliative care services and these problems should be incorporated into the risk mitigation algorithms.

Legal entity responsible for the study: The authors.

Funding: Has not received any funding.

Disclosure: All authors have declared no conflicts of interest.

https://doi.org/10.1016/j.annonc.2020.08.1788

Organizational challenges and oncological activity volumes during the SARS-CoV-2 epidemic peak in Verona, Italy

A. Pastorino1, M.E. Negru1, A. Viganò1, F. Vaira1, A. Tognoni1, A. Ferrari1, I. Ricci1, M. Romitì1, F. Olcese1, A. Milano1, F. Cozzani1, C. Aschele1

1Medical Oncology, Ospedale Sant’Andrea, La Spesia, Italy

Background: The reorganization of oncologic follow-up was crucial to maintain oncologic care and reduce patient exposure during SARS-CoV-2 pandemic.

Methods: Patients scheduled for follow-up oncologic visits during the lockdown period (March 9th - May 4th 2020) were included in a program of telematic follow-up (TFU) developed at the Medical Oncology Unit of Sant’Andrea and San Bartolomeo Hospital in La Spezia, Italy. Eligibility for TFU was determined through a pre-screening of medical charts based on tumor type, risk of relapse, geographic accessibility and DFS. Pre-calls were made by skilled nurses to assess pts’ availability for next-day phone call and to assess availability of laboratory test and imaging results. A TFU form was conceived to collect pts’ clinical history, symptoms, body-weight, ongoing medical therapies, DFS, blood tests and imaging results (from Hospital imaging repository or acquired in the pre-call). Pts without signs/symptoms of relapse were scheduled for...